{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:11:38Z","timestamp":1791389498006,"version":"4.3.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ygyno.2021.08.027","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T08:14:20Z","timestamp":1631175260000},"page":"220-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers"],"prefix":"10.1016","volume":"163","author":[{"given":"Sahana","family":"Somasegar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hoppenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Kuchta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Sereika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janardan","family":"Khandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hurteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilley Jenkins","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2021.08.027_bb0005","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2021.08.027_bb0010","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1535-7163.MCT-17-1107","article-title":"Clinical next-generation sequencing for precision oncology in rare cancers","volume":"17","author":"Groisberg","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2021.08.027_bb0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrc.2016.35","article-title":"Defining actionable mutations for oncology therapeutic development","volume":"16","author":"Carr","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.027_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2021.08.027_bb0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nat. Genet."},{"issue":"25","key":"10.1016\/j.ygyno.2021.08.027_bb0030","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.ygyno.2021.08.027_bb0035","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2021.08.027_bb0040","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10106","key":"10.1016\/j.ygyno.2021.08.027_bb0045","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ygyno.2021.08.027_bb0050","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1097\/IGC.0000000000001089","article-title":"Veliparib monotherapy to patients with BRCA germ line mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: a phase I\/II study","volume":"27","author":"Steffensen","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"25","key":"10.1016\/j.ygyno.2021.08.027_bb0055","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.027_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient Cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6349","key":"10.1016\/j.ygyno.2021.08.027_bb0065","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2021.08.027_bb0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"7447","key":"10.1016\/j.ygyno.2021.08.027_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"7488","key":"10.1016\/j.ygyno.2021.08.027_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature12881","article-title":"Landscape of genomic alterations in cervical carcinomas","volume":"506","author":"Ojesina","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.027_bb0085","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ygyno.2019.02.005","article-title":"Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients","volume":"153","author":"Rodriguez-Freixinos","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.027_bb0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ygyno.2016.02.021","article-title":"Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers","volume":"141","author":"Rodriguez-Rodriguez","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.027_bb0095","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/cam4.2064","article-title":"Impact of molecular testing in clinical practice in gynecologic cancers","volume":"8","author":"Huang","year":"2019","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/j.ygyno.2021.08.027_bb0100","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3349\/ymj.2019.60.10.914","article-title":"Integrating a next generation sequencing panel into clinical practice in ovarian cancer","volume":"60","author":"Lee","year":"2019","journal-title":"Yonsei Med. J."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.027_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2015.12.001","article-title":"Genomic testing and precision medicine--what does this mean for gynecologic oncology?","volume":"140","author":"Liu","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2021.08.027_bb0110","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"26","key":"10.1016\/j.ygyno.2021.08.027_bb0115","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2021.08.027_bb0120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/1759-7714.13272","article-title":"Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP)","volume":"11","author":"Ruiz-Pati\u00f1o","year":"2020","journal-title":"Thorac. Cancer"},{"issue":"15","key":"10.1016\/j.ygyno.2021.08.027_bb0125","doi-asserted-by":"crossref","first-page":"19840","DOI":"10.18632\/oncotarget.7835","article-title":"Impact of molecular profiling on overall survival of patients with advanced ovarian cancer","volume":"7","author":"Herzog","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ygyno.2021.08.027_bb0130","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.027_bb0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.08.027_bb0140","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.08.027_bb0145","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamadermatol.2018.5071","article-title":"Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia","volume":"155","author":"Freites-Martinez","year":"2019","journal-title":"JAMA Dermatol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:56:57Z","timestamp":1758772617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821013251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0090825821013251"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.027","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}